PapersFlow Research Brief
Glioma Diagnosis and Treatment
Research Guide
What is Glioma Diagnosis and Treatment?
Glioma diagnosis and treatment encompasses the genetic, molecular, and clinical approaches to identifying and managing gliomas, including glioblastoma and medulloblastoma, through classification systems, molecular markers like IDH mutations and MGMT promoter methylation, and therapies such as temozolomide combined with radiotherapy.
The field includes 148,520 works on glioma genetics, classification, and treatment strategies. Stupp et al. (2005) in "Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma" demonstrated that adding temozolomide to radiotherapy extended survival in newly diagnosed glioblastoma patients. WHO classifications from Louis et al. (2007, 2016, 2021) integrate molecular features like IDH mutations for precise tumor categorization.
Topic Hierarchy
Research Sub-Topics
Glioblastoma Molecular Classification
This sub-topic covers genomic subtyping based on IDH, EGFR, and NF1 alterations using integrated multi-omics. Researchers develop classifiers for prognosis and personalized therapy selection.
Temozolomide in Glioma Treatment
This sub-topic examines TMZ efficacy, resistance mechanisms, and MGMT methylation as biomarkers. Researchers conduct trials on dosing schedules and combination regimens.
IDH Mutations in Gliomas
This sub-topic investigates IDH1/2 mutant gliomas' biology, metabolic reprogramming, and therapeutic vulnerabilities. Researchers study mutation prevalence across grades and prognostic value.
Radiotherapy for Glioblastoma
This sub-topic explores radiation protocols, dose fractionation, and radioresistance in GBM stem cells. Researchers assess combined modality trials and imaging for response.
Immunotherapy in Neuro-Oncology
This sub-topic evaluates checkpoint inhibitors, CAR-T cells, and vaccines for glioma immune modulation. Researchers address tumor microenvironment barriers like myeloid suppression.
Why It Matters
Glioma diagnosis and treatment directly impacts patient survival, as shown by Stupp et al. (2005), where temozolomide with radiotherapy increased median survival from 12.1 to 14.6 months in glioblastoma patients, with 5-year survival rising from 2% to 9.8% per the 2009 analysis by Stupp et al. Hegi et al. (2005) in "MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma" established that MGMT promoter methylation predicts temozolomide response, guiding personalized therapy in neuro-oncology. Population data from Ostrom et al. (2013) in "CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010" quantify glioma incidence, informing epidemiology-driven public health strategies. These advances enable targeted interventions in high-grade gliomas, reducing reliance on surgery alone.
Reading Guide
Where to Start
"Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma" by Stupp et al. (2005) is the starting point, as it establishes the foundational treatment standard with clear survival data and minimal toxicity, cited 20,925 times.
Key Papers Explained
Stupp et al. (2005) "Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma" introduced the standard regimen, validated at 5 years by Stupp et al. (2009) "Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma". Hegi et al. (2005) "MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma" explained response predictors. Louis et al. (2016) "The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary" and (2021) provided molecular frameworks, while Verhaak et al. (2010) and McLendon (2008) defined genomic subtypes building on TCGA data.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints explore molecularly matched therapies in the N2M2 umbrella trial (2025), AI for glioma detection and segmentation, and advanced neuroimaging for systemic therapies. FDA fast track for zotiraciclib targets recurrent IDH-mutant high-grade gliomas (2025), with IND clearance for SRN-101 immuno-gene therapy (2026). UNC breakthrough and 5G platform trial address glioblastoma resistance.
Papers at a Glance
In the News
FDA Clears IND for Investigational Program in Recurrent ...
The FDA has cleared an investigational new drug (IND) application for SRN-101, an adeno-associated virus (AAV)–based immuno-gene therapy, for the treatment of adult patients with recurrent high-gra...
New breakthrough could modernize treatment for ...
Researchers at the UNC School of Medicine and the UNC Eshelman School of Pharmacy have made a breakthrough that could modernize treatment for glioblastoma, a fast-growing and deadly form of brain c...
Fast, flexible, and first-in-brain: how the 5G trial is taking on ...
Ultimately, this led them to bid, successfully, for £3m funding from Minderoo and Cancer Research UK, enabling the pair to launch, in October 2024, a first-of-its-kind platform trial for UK patient...
FDA grants fast track designation to zotiraciclib for the treatment of recurrent high-grade glioma
An oral drug called zotiraciclib for patients with recurrent IDH-mutant gliomas has been granted Fast Track Designation for the treatment of patients with recurrent high-grade gliomas with IDH1 or ...
NBTS-Funded Discovery Drives New Glioblastoma Clinical ...
- News - Contact - Search - Give Search BACK to News # Turning Resistance into Vulnerability: NBTS-Funded Discovery Drives New Glioblastoma Clinical Trial
Code & Tools
classification, molecular marker prediction, and survival estimation. In the final step, the outputs of the model are used to generate automated ra...
📚 Overview TaDiff-Net is a novel end-to-end network that: Generates future predictions of tumor masks and multi-parametric MRI images Supp...
## Repository files navigation # Low-Grade-Glioma-Segmentation ## Table of Contents
## Directory organization ``` `fastglioma/ ├──fastglioma/ # Library for FastGlioma training │├──datasets/ # PyTorch OpenSRH datasets │├──losses/ ...
Guericke University Magdeburg, Germany. The deep learning framework for this project is TensorFlow 2.0.
Recent Preprints
Glioblastoma—A Contemporary Overview of Epidemiology ...
plays an important role, promoting immune escape and weakening the effectiveness of systemic therapies, including immunotherapy. The aim of this review is to summarize the current state of knowledg...
Molecularly matched targeted therapies plus radiotherapy in glioblastoma: the phase 1/2a N2M2 umbrella trial
Advances in molecular understanding and diagnostic precision of glioblastoma enable the identification of key genetic alterations in a timely manner and, in principle, allow treatments with targete...
Advanced Neuroimaging and Emerging Systemic Therapies in Glioblastoma: Current Evidence and Future Directions
Despite technological progress, glioblastoma (GBM) continues to confer dismal prognoses. Modern neuroimaging methods are assuming an ever greater role in diagnosing and monitoring brain tumors. Thi...
Artificial Intelligence in the Diagnosis and Treatment of Brain ...
Brain gliomas are highly infiltrative and heterogenous tumors, whose early and accurate detection as well as therapeutic management are challenging. Artificial intelligence (AI) has the potential t...
Low-Grade Gliomas - StatPearls - NCBI Bookshelf
## Treatment / Management
Latest Developments
Recent developments in glioma diagnosis and treatment research include a promising new gene therapy trial for glioblastoma using an engineered adeno-associated virus (AAV) injected directly into tumors, which seeks out and infiltrates glioblastoma cells, anticipated to start in early 2026 (Brain Tumour Research). Additionally, a combination therapy has shown effectiveness in recent research, and innovative approaches such as focused ultrasound-mediated blood-brain barrier opening combined with chemotherapy are being explored in early-stage trials (UNC Healthcare, Fus Foundation). Advances in immunotherapy, including engineered virus therapies and CAR T cell trials targeting glioblastoma, are also ongoing (Breakthrough Cancer, Nature Medicine, Yale Medicine). Furthermore, AI-driven radiomics and deep learning are being investigated for tumor classification and molecular profiling, enhancing diagnostic accuracy (MDPI).
Sources
Frequently Asked Questions
What is the survival benefit of temozolomide with radiotherapy for glioblastoma?
Stupp et al. (2005) in "Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma" reported a median survival of 14.6 months with temozolomide plus radiotherapy versus 12.1 months with radiotherapy alone. The 5-year analysis by Stupp et al. (2009) confirmed sustained benefit with minimal added toxicity. This regimen remains standard for newly diagnosed cases.
How does MGMT promoter methylation affect temozolomide response?
Hegi et al. (2005) in "MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma" found that glioblastoma patients with methylated MGMT promoters had significantly longer survival with temozolomide. Unmethylated cases showed no such benefit. MGMT status testing is now routine for treatment decisions.
What molecular changes define the 2016 WHO classification of CNS tumors?
Louis et al. (2016) in "The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary" incorporated IDH mutations and 1p/19q codeletion for glioma subtyping. This shifted from purely histological to integrated molecular-histological diagnosis. The 2021 update by Louis et al. further refined these criteria.
What subtypes of glioblastoma were identified by genomic analysis?
Verhaak et al. (2010) in "Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1" defined four subtypes based on gene expression: proneural, neural, classical, and mesenchymal. These correlate with PDGFRA, IDH1, EGFR, and NF1 alterations. Subtyping aids prognosis and targeted therapy selection.
Why are glioma stem cells linked to radioresistance?
Bao et al. (2006) in "Glioma stem cells promote radioresistance by preferential activation of the DNA damage response" showed that glioma stem cells activate DNA repair pathways more efficiently post-radiotherapy. This contributes to tumor recurrence. Targeting stem cells may enhance treatment efficacy.
What is the incidence of primary brain tumors in the US?
Ostrom et al. (2013) in "CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2006-2010" reported data from the largest US population-based registry covering all primary CNS tumors. Incidence rates inform epidemiology and resource allocation. CBTRUS collaborates with CDC and NCI.
Open Research Questions
- ? How can glioma stem cell radioresistance be overcome to improve radiotherapy outcomes?
- ? What core genomic pathways drive glioblastoma progression beyond known subtypes?
- ? How do IDH mutations interact with other alterations to influence glioma classification and treatment response?
- ? What mechanisms enable immune escape in glioblastoma despite immunotherapy advances?
- ? How can molecular profiling be integrated into real-time treatment matching for recurrent gliomas?
Recent Trends
Preprints highlight AI-driven glioma segmentation, radiology report generation, and molecular marker prediction via tools like Radiology-agentic-system and FastGlioma.
N2M2 trial tests targeted therapies with radiotherapy based on genetic alterations.
2025FDA fast track for zotiraciclib in IDH-mutant recurrent gliomas and IND for SRN-101 AAV immuno-gene therapy (2026) mark regulatory progress.
2025UNC breakthrough modernizes glioblastoma treatment , with 5G trial launching platform testing (2025).
2026Research Glioma Diagnosis and Treatment with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Glioma Diagnosis and Treatment with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers